2-(4-fluorophenylamino)-4-(4-fluorophenyl)thiazole | 1554-59-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(4-fluorophenylamino)-4-(4-fluorophenyl)thiazole
• 英文别名: 4-fluorophenyl-2-(N-4-fluorophenylamino)thiazole；N,4-bis(4-fluorophenyl)thiazol-2-amine；(4-fluoro-phenyl)-[4-(4-fluoro-phenyl)-thiazol-2-yl]-amine；2-<4-Fluor-phenylamino>-4-<4-fluor-phenyl>-thiazol；N,4-bis(4-fluorophenyl)-1,3-thiazol-2-amine
• CAS: 1554-59-2
• 化学式: C₁₅H₁₀F₂N₂S
• mdl: MFCD00128402
• 分子量: 288.321
• InChiKey: ZRUFADCCSVYTQW-UHFFFAOYSA-N

物化性质

• 熔点：
  110 °C
• 沸点：
  421.7±55.0 °C(Predicted)
• 密度：
  1.360±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  53.2
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  1-(4-fluorophenyl)-2-(p-tolylsulfonyloxy)ethanone 以 甲醇 为溶剂， 反应 5.17h， 生成 2-(4-fluorophenylamino)-4-(4-fluorophenyl)thiazole
  参考文献：
  名称：

  Prakash, Om; Pundeer, Rashmi; Chaudhri, Vishwas, Journal of the Indian Chemical Society, 2004, vol. 81, # 9, p. 786 - 788

  摘要：

  DOI：

文献信息

• [EN] SUBSTITUTED 4-ARYLTHIAZOLES AND PROCESS OF PREPARATION THEREOF<br/>[FR] 4-ARYLTHIAZOLES SUBSTITUÉS ET PROCÉDÉ DE PRÉPARATION DE CES DERNIERS
  申请人：COUNCIL SCIENT IND RES

  公开号：WO2012164572A1

  公开（公告）日：2012-12-06

  The present invention relates to novel substituted 4-arylthiazoles, their preparation, and to their use as therapeutic agents, particularly in the prevention or treatment of tuberculosis. The resent invention articularl relates to com ounds of formula A:

  本发明涉及新型取代的4-芳基噻唑化合物，其制备以及作为治疗剂的用途，特别是在预防或治疗结核病方面。该发明特别涉及公式A的化合物。
• [EN] GP130 MODULATORS<br/>[FR] MODULATEURS DE GP130
  申请人：UNIV CALIFORNIA

  公开号：WO2018027193A1

  公开（公告）日：2018-02-08

  There are provided, inter alia, compounds and methods useful for the treatment of neurological conditions, such as neurological disorders and neurodegenerative diseases, including Alzheimer's Disease.

  提供了一些化合物和方法，用于治疗神经系统疾病，如神经障碍和神经退行性疾病，包括阿尔茨海默病。
• SUBSTITUTED 4-ARYLTHIAZOLES AND PROCESS OF PREPARATION THEREOF
  申请人：Singh Supriya

  公开号：US20140235863A1

  公开（公告）日：2014-08-21

  The present invention relates to novel substituted 4-arylthiazoles, their preparation, and to their use as therapeutic agents, particularly in the prevention or treatment of tuberculosis. The present invention particularly relates to compounds of formula A:

  本发明涉及新型取代的4-芳基噻唑，其制备方法，以及其作为治疗剂的用途，特别是在结核病的预防或治疗方面。本发明特别涉及A式化合物。
• ANTICANCER AGENT COMPOSITION
  申请人：Carna Biosciences, Inc.

  公开号：EP3100742A1

  公开（公告）日：2016-12-07

  Provided is a pharmaceutical composition comprising a Cdc7 inhibitor and an M phase promoter. In particular, the Cdc7 inhibitor contained in the pharmaceutical composition is a furanone derivative represented by formula (I), or a pharmaceutically acceptable salt thereof. (In the formula, A is -COOR1 or a hydrogen atom; R1 is a hydrogen atom, an optionally substituted hydrocarbon group, or an optionally substituted heterocycle; R2 and R3 are the same or different and are each a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted phenyl group, an optionally substituted heterocycle, an optionally substituted heterocyclic condensed ring, or an optionally substituted amino group. Alternatively, R2 and R3 may, together with the nitrogen atoms bonding the same, form an optionally substituted heterocycle or optionally substituted heterocyclic condensed ring. R4 is a hydrogen atom or halogen atom. However, if A is -COOR1, R2 and R3 are not both simultaneously optionally substituted amino groups. When A is a hydrogen atom, R3 is a hydrogen atom.)

  本发明提供了一种药物组合物，其中包含一种 Cdc7 抑制剂和一种 M 期促进剂。特别是，药物组合物中所含的 Cdc7 抑制剂是由式（I）表示的呋喃酮衍生物或其药学上可接受的盐。(式中，A为-COOR1或氢原子；R1为氢原子、任选取代的烃基或任选取代的杂环；R2和R3相同或不同，各自为氢原子、任选取代的烃基、任选取代的苯基、任选取代的杂环、任选取代的杂环缩合环或任选取代的氨基。或者，R2 和 R3 可与结合在一起的氮原子一起形成任选取代的杂环或任选取代的杂环缩合环。R4 是氢原子或卤素原子。但是，如果 A 是-COOR1，R2 和 R3 不能同时是任选取代的氨基。当 A 为氢原子时，R3 为氢原子）。
• GP130 modulators
  申请人：THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

  公开号：US10947207B2

  公开（公告）日：2021-03-16

  There are provided, inter alia, compounds and methods useful for the treatment of neurological conditions, such as neurological disorders and neurodegenerative diseases, including Alzheimer's Disease.

  除其他外，还提供了用于治疗神经系统疾病（如神经系统紊乱和神经退行性疾病，包括阿尔茨海默病）的化合物和方法。